Ferguson Wellman Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$165M Buy
656,778
+6,367
+1% +$1.37M 2.02% 11
2026
Q1
$141M Sell
650,411
-87
-0% -$19.3K 1.93% 12
2025
Q4
$149M Buy
650,498
+2,813
+0.4% +$641K 2.38% 8
2025
Q3
$150M Buy
647,685
+3,260
+0.5% +$664K 2.43% 7
2025
Q2
$120M Buy
644,425
+5,132
+0.8% +$954K 2.11% 11
2025
Q1
$134M Buy
639,293
+11,139
+2% +$2.17M 2.6% 7
2024
Q4
$112M Sell
628,154
-5,592
-0.9% -$1.03M 2.12% 9
2024
Q3
$125M Sell
633,746
-2,899
-0.5% -$541K 2.42% 8
2024
Q2
$109M Sell
636,645
-15,173
-2% -$2.51M 2.22% 9
2024
Q1
$119M Buy
651,818
+102,399
+19% +$17.6M 2.42% 7
2023
Q4
$85.1M Buy
549,419
+528
+0.1% +$77K 1.91% 12
2023
Q3
$81.8M Sell
548,891
-42,976
-7% -$6.31M 2% 10
2023
Q2
$79.7M Sell
591,867
-161
-0% -$23.6K 1.87% 11
2023
Q1
$94.4M Sell
592,028
-6,621
-1% -$1.01M 2.37% 6
2022
Q4
$96.7M Buy
598,649
+278,773
+87% +$42.7M 2.52% 7
2022
Q3
$42.9M Sell
319,876
-73,875
-19% -$10.6M 1.68% 13
2022
Q2
$60.3M Sell
393,751
-98,180
-20% -$15M 2.24% 5
2022
Q1
$79.7M Sell
491,931
-7,456
-1% -$1.08M 2.51% 5
2021
Q4
$67.6M Buy
499,387
+13,049
+3% +$1.54M 1.97% 8
2021
Q3
$52.5M Buy
486,338
+4,070
+0.8% +$465K 1.69% 11
2021
Q2
$54.3M Sell
482,268
-10,397
-2% -$1.17M 1.77% 12
2021
Q1
$53.3M Sell
492,665
-292,648
-37% -$31.3M 1.85% 10
2020
Q4
$84.1M Buy
785,313
+9,228
+1% +$887K 2.06% 8
2020
Q3
$68M Buy
776,085
+112,673
+17% +$10.6M 1.87% 10
2020
Q2
$65.1M Buy
663,412
+11,561
+2% +$1.02M 1.99% 9
2020
Q1
$49.7M Buy
651,851
+112,726
+21% +$9.6M 1.86% 12
2019
Q4
$47.7M Buy
539,125
+9,714
+2% +$806K 1.41% 16
2019
Q3
$40.1M Buy
529,411
+39,847
+8% +$2.73M 1.28% 21
2019
Q2
$35.6M Buy
489,564
+212,961
+77% +$16.7M 1.18% 24
2019
Q1
$22.3M Sell
276,603
-536,494
-66% -$43.9M 0.76% 41
2018
Q4
$75M Sell
813,097
-21,235
-3% -$1.87M 2.88% 5
2018
Q3
$78.9M Buy
834,332
+135,551
+19% +$12.9M 2.59% 5
2018
Q2
$64.7M Buy
698,781
+6,875
+1% +$671K 2.26% 6
2018
Q1
$65.5M Sell
691,906
-6,873
-1% -$755K 2.32% 5
2017
Q4
$67.6M Buy
698,779
+2,161
+0.3% +$204K 2.33% 3
2017
Q3
$61.9M Sell
696,618
-55,132
-7% -$4.2M 2.24% 4
2017
Q2
$54.5M Buy
751,750
+58,554
+8% +$3.94M 2.05% 5
2017
Q1
$45.2M Buy
693,196
+8,510
+1% +$535K 1.74% 9
2016
Q4
$42.9M Sell
684,686
-3,400
-0.5% -$208K 1.75% 9
2016
Q3
$43.4M Sell
688,086
-72,727
-10% -$4.71M 1.86% 11
2016
Q2
$47.1M Buy
760,813
+115,764
+18% +$7.05M 1.98% 8
2016
Q1
$36.8M Buy
645,049
+5,586
+0.9% +$311K 1.57% 14
2015
Q4
$37.9M Buy
639,463
+68,354
+12% +$3.94M 1.56% 13
2015
Q3
$31.1M Sell
571,109
-14,783
-3% -$962K 1.38% 17
2015
Q2
$39.4M Sell
585,892
-11,533
-2% -$753K 1.63% 9
2015
Q1
$35M Sell
597,425
-212,771
-26% -$12.9M 1.44% 16
2014
Q4
$53M Buy
810,196
+26,805
+3% +$1.69M 2.13% 2
2014
Q3
$45.2M Buy
783,391
+296,508
+61% +$16.5M 1.93% 5
2014
Q2
$27.5M Sell
486,883
-84,595
-15% -$4.44M 1.16% 26
2014
Q1
$29.4M Sell
571,478
-2,135
-0.4% -$108K 1.31% 22
2013
Q4
$30.3M Sell
573,613
-170,935
-23% -$8.4M 1.37% 18
2013
Q3
$33.3M Buy
744,548
+202,339
+37% +$8.97M 1.65% 8
2013
Q2
$22.4M Buy
+542,209
New +$23.7M 1.73% 22

Other funds holding ABBV

Ferguson Wellman Capital Management's ABBV Position: Q2 2026 in Review

Ferguson Wellman Capital Management increased its AbbVie (ABBV) stake by 0.98% in Q2 2026, buying an estimated $1.37M and bringing the position to 656,778 shares worth $165M. The position accounts for 2.02% of the portfolio, ranked #11.

Ferguson Wellman Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 1,580 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ferguson Wellman Capital Management held 656,778 shares of AbbVie worth $165M as of Q2 2026.
  • Ferguson Wellman Capital Management bought 6,367 AbbVie shares in Q2 2026, an estimated $1.37M.
  • AbbVie made up 2.02% of Ferguson Wellman Capital Management's portfolio in Q2 2026, its #11 holding.
  • Ferguson Wellman Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 1,580 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ferguson Wellman Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.